Fulcrum Therapeutics FULC 深 沪
等待开盘 04-03 09:30:00 美东时间
8.04
+0.560
+7.49%
华盛通- 最 高8.11
- 今 开7.31
- 成交量 90.07万股
- 最 低 7.30
- 昨 收 7.48
- 总市值 5.35亿
- 52周最高 15.7399
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.71
- 委 比 -17.56%
- 总股本 6660.02万
- 历史最高 33.098
- 量 比 0.67
- 振 幅 10.83%
- 历史最低 2.25
- 每 手 1
- 风险率 2.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
03-30 20:04
MedicAlert Foundation, SCDAA And Fulcrum Therapeutics Partner To Help Streamline And Expedite ED Care For People Living With Sickle Cell Disease Through Rapid Access To Patient-Specific Care Plans
MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle
03-19 20:26
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three organizations collaborate to improve emergency care for sickle cell disease patients by providing a smart medical ID card with quick access to personalized care plans, aiming to reduce delays and enhance treatment during pain crises.
03-19 12:00
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) granted non-statutory stock options to a new employee as an inducement for joining the company. The employee received 34,000 options with an exercise price of $7.81 per share, vesting over four years. Fulcrum Therapeutics focuses on developing small molecules for genetically defined rare diseases, with a lead program targeting sickle cell disease.
03-06 21:30
Fulcrum Therapeutics to Present at Leerink Partners Global Healthcare Conference in Miami
Fulcrum Therapeutics to Present at Leerink Partners Global Healthcare Conference in Miami Fulcrum Therapeutics Inc. said its management will present at the Leerink Partners Global Healthcare Conference in Miami, Florida, on March 10, 2025 at 1:00 p.m. ET. The presentation webcast will be available a
03-03 21:30
What's Going On With Fulcrum Therapeutics Stock Tuesday?
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease patients.
02-24 22:48
Fulcrum Therapeutics Q4 EPS $(0.31), Inline
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
02-24 20:42
Fulcrum Therapeutics GAAP EPS of -$0.31 in-line
Fulcrum Therapeutics press release (FULC): Q4 GAAP EPS of -$0.31 in-line. Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029. Based on its curre...
02-24 20:20
Fulcrum Therapeutics reports bigger Q4 net loss
Fulcrum Therapeutics reports bigger Q4 net loss Overview Biopharmaceutical firm reported Q4 net loss of $20.3 mln Company ended 2025 with $352.3 mln in cash, cash equivalents, and marketable securities Announced positive 12-week results from Phase 1b PIONEER trial in sickle cell disease Outlook Fulc
02-24 20:17
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 65.0% to $12.26...
02-24 20:05
